|
Technology Overview The AttoSense™ assays run on the proprietary MassARRAY® PCR-MS system developed by Sequenom Corporation, and licensed exclusively by SensiGen for its proprietary assays. The MassARRAY® system is a highly automated, widely established PCR-MS platform capable of identifying more than 30 target sequences in a single reaction and with capacity to process nearly 2,000 samples in a single run. The "attomolar" (10-18 molar) sensitivity levels of SensiGen's assays represent an unprecedented 2+ orders of magnitude improvement over the current state of the art. Moreover, the AttoSense™ assays can work with any biological medium (blood, urine, tissue, etc.) and readily deliver genotype specific, fully quantitative results, in absolute or relative terms (e.g. “viral load”) as opposed to returning only “positive” or “negative” results in an aggregate sense. AttoSense™ assays currently in development include: AttoSense™ HPV Assay For more information on the MassARRAY® system from Sequenom, follow this link: www.sequenom.com FOR INVESTIGATIONAL USE ONLY: These statements have not been evaluated by the FDA. |
|
SensiGen has developed a new type of gene-based molecular diagnostic testing technology, called AttoSense™ which has revolutionized the already advanced art of molecular level detection. The AttoSense™ technology combines "real-competitive" polymerase chain reaction (rc-PCR) with matrix-assisted laser desorption/ionization-time of flight mass spectrometry (MALDI-TOF MS), collectively called PCR-MS to enable unique, multiplex assays that can reliably and accurately detect as few as one to three target sequences in any biological sample. 